×
About 428 results

ALLMedicine™ Nail Psoriasis Center

Research & Reviews  143 results

Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of pso...
https://www.ncbi.nlm.nih.gov/pubmed/34494957
Clinical and Experimental Rheumatology; Nash P, Mease PJ et. al.

Sep 9th, 2021 - To evaluate the impact of secukinumab on nail psoriasis and other psoriatic disease manifestations in patients with psoriatic arthritis (PsA) with concomitant nail psoriasis from the FUTURE 5 study. Eligible patients were randomly allocated to rec...

Challenge of Nail Psoriasis: An Update Review.
https://doi.org/10.1007/s12016-021-08896-9 10.2147/dddt.S136986 10.1186/s12895-020-00099-7 10.1111/jdv.13979 10.1159/000246274 10.1159/000495291 10.1016/j.det.2018.11.001 10.1016/s0140-6736(18)30830-4 10.2340/00015555-0253 10.1111/ijd.12562 10.2340/00015555-2605 10.1016/j.clindermatol.2007.08.015 10.1111/j.0022-202X.2005.23927.x 10.1111/jdv.13970 10.1615/CritRevTherDrugCarrierSyst.2020029259 10.1093/rheumatology/keh198 10.1093/rheumatology/kel214 10.1016/j.semarthrit.2014.05.002 10.5114/reum.2017.68912 10.1016/j.jaad.2005.07.073 10.1111/j.1365-2133.1996.tb07947.x 10.1211/0022357991772448 10.1111/myc.12592 10.1111/j.1365-4362.1983.tb02124.x 10.1097/dad.0000000000001244 10.1136/annrheumdis-2014-205839 10.2165/11597000-000000000-00000 10.1111/bjd.12354 10.1016/j.jaad.2013.02.009 10.1007/s00403-012-1274-9 10.1159/000332974 10.1111/j.1365-2230.2006.02305.x 10.1007/s10227-002-0143-0 10.1111/j.1468-3083.2011.04289.x 10.1111/j.1468-3083.2009.03364.x 10.1111/jdv.14141 10.4103/0019-5154.135470 10.1159/000448253 10.2340/00015555-3098 10.1590/abd1806-4841.20142633 10.1111/j.1468-3083.2009.03363.x 10.1016/j.det.2006.03.014 10.1155/2018/8251097 10.1159/000343607 10.1097/rhu.0000000000000054 10.1186/s42358-019-0081-9 10.1007/s10067-009-1292-y 10.1016/j.crad.2012.07.018 10.1136/ard.2007.075101 10.1016/j.semarthrit.2010.05.009 10.1093/rheumatology/ker078 10.1016/j.semarthrit.2017.05.002 10.1159/000508165 10.1111/j.1529-8019.2012.01521.x 10.4103/0019-5154.156377 10.5114/ada.2017.65618 10.1016/j.jaad.2007.11.026 10.1111/1346-8138.13438 10.3899/jrheum.170962 10.1111/jdv.12330 10.4103/idoj.IDOJ_51_19 10.1046/j.1365-4362.2001.01261-4.x 10.5826/dpc.0804a06 10.1016/s0190-9622(86)70097-2 10.1111/myc.12542 10.1111/j.1439-0507.2011.02053.x 10.1111/jdv.12862 10.1159/000018281 10.1046/j.1365-2133.2003.05725.x 10.1159/000068469 10.1016/j.jaad.2014.02.010 10.1016/j.jaad.2019.01.072 10.1067/s0190-9622(03)00910-1 10.1016/j.jaad.2013.06.051 10.1007/s40265-016-0564-5 10.1111/bjd.12664 10.1111/j.1468-3083.2009.03344.x 10.1016/j.clindermatol.2007.10.026 10.1111/j.1529-8019.2012.01516.x 10.3109/09546639909056030 10.1111/j.1468-3083.2005.01253.x 10.1046/j.1365-2133.1998.02462.x 10.1159/000323004 10.2340/00015555-0401 10.1159/000202179 10.1080/00015550252948220 10.1111/j.1468-3083.2008.02679.x 10.4103/0378-6323.174389 10.1001/jama.2020.4006 10.1111/j.1365-2230.2006.02167.x 10.5070/D31T20Z9WW 10.1080/09546630902787585 10.1159/000248005 10.1159/000210782 10.1159/000107635 10.2310/7750.2013.13059 10.1016/s0161-6420(98)99043-1 10.1002/lsm.22122 10.4274/atfm.43534 10.4103/ijdvl.IJDVL_632_18 10.1111/j.1365-4632.2012.05611.x 10.1111/j.1346-8138.1998.tb02386.x 10.1001/archderm.1974.01630110033006 10.1001/archderm.144.11.1457 10.1159/000333362 10.1001/jamadermatol.2014.5460 10.1016/j.phymed.2014.02.013 10.1111/j.1468-3083.2009.03209.x 10.2147/ccid.S61659 10.1159/000478257 10.1111/j.1365-2133.2009.09212.x 10.1016/j.jaad.2011.12.015 10.1111/j.1468-3083.2010.03938.x 10.1016/0190-9622(95)90189-2 10.1001/archdermatol.2008.600 10.1517/14728214.2015.1010509 10.1111/j.1468-3083.2010.03927.x 10.1056/NEJMoa1010858 10.2340/00015555-2081 10.1111/bjd.17689 10.1016/j.jaad.2018.11.057 10.1517/14712598.2013.783561 10.1111/jdv.14033 10.1111/j.1468-3083.2009.03211.x 10.1111/1346-8138.12229 10.1111/bjd.12060 10.1517/14712598.2013.736960 10.3109/09546634.2011.646939 10.1016/s0140-6736(05)67566-6 10.1016/j.jaad.2004.09.012 10.1111/j.1365-2133.2008.08686.x 10.1016/j.jaad.2007.07.042 10.1016/j.jaad.2016.11.042 10.1016/j.jaad.2016.11.041 10.1001/jamadermatol.2018.0793 10.1111/jdv.15793 10.1136/ard.2009.111856 10.1186/ar3054 10.3109/09546634.2010.519376 10.1001/archdermatol.2010.384 10.1111/jdv.12553 10.1111/j.1468-3083.2009.03453.x 10.1056/NEJMoa1607017 10.1007/s13555-020-00383-x 10.1111/j.1346-8138.2011.01347.x 10.1111/bjd.12632 10.1159/000334482 10.3109/09546634.2011.607796 10.1111/bjd.17351 10.1056/NEJMoa1109997 10.1111/jdv.12996 10.3899/jrheum.170429 10.1016/s0140-6736(17)31429-0 10.1111/1346-8138.13927 10.1111/1346-8138.14504 10.1016/s0140-6736(12)60642-4 10.1016/j.jaad.2015.09.001 10.1111/jdv.14738 10.1111/bjd.14018 10.1111/1346-8138.13956 10.1016/j.jdermsci.2017.05.004
Clinical Reviews in Allergy & Immunology; Ji C, Wang H et. al.

Sep 4th, 2021 - Nail psoriasis is a refractory disease that affects 50-79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA). The pathogenesis of nail psoriasis is still not fully illuminated, although some peculiar inflammatory cyt...

Apremilast improves quality of life and ultrasonography parameters in patients with nai...
https://doi.org/10.1111/1346-8138.16074
The Journal of Dermatology; Muñoz-Santos C, Sola-Ortigosa J et. al.

Aug 15th, 2021 - Specific studies on apremilast for nail psoriasis are lacking. Our objective was to evaluate the nail-specific patient-reported outcomes, clinical efficacy, ultrasound (US) parameters, and safety of apremilast for nail psoriasis. We conducted a pr...

Psoriatic arthritis.
https://doi.org/10.1038/s41572-021-00293-y 10.1056/NEJMra1505557 10.1093/rheumatology/kez325 10.1136/annrheumdis-2012-201706 10.1136/ard.2011.150102 10.1038/ng.688 10.1002/art.38376 10.1016/j.jaad.2018.06.027 10.1016/j.semarthrit.2018.01.003 10.1093/rheumatology/kes324 10.1007/s40257-017-0332-7 10.1016/j.rdc.2020.01.003 10.1002/art.23240 10.1002/anr.1780320810 10.1177/2475530318799072 10.1002/art.40884 10.1016/j.berh.2021.101692 10.1038/s41584-019-0175-0 10.1002/art.21972 10.1016/j.jaad.2015.05.001 10.1136/annrheumdis-2017-211109 10.1007/s00296-020-04775-2 10.1007/s40744-020-00215-6 10.1177/1759720X21998279 10.1016/j.rdc.2015.07.001 10.1093/rheumatology/ket343 10.1177/1203475420977477 10.1097/BOR.0000000000000388 10.3899/jrheum.201163 10.1136/annrheumdis-2017-211284 10.1111/1756-185X.13987 10.1093/rheumatology/keaa692 10.1093/rheumatology/keaa062 10.1016/j.rdc.2015.07.002 10.1038/s41598-020-61981-5 10.1002/art.33415 10.1016/j.ajhg.2014.07.002 10.1136/annrheumdis-2017-211414 10.1097/BOR.0000000000000720 10.1136/annrheumdis-2014-205461 10.1038/ncomms8741 10.1002/art.37885 10.1111/bjd.18227 10.1136/annrheumdis-2016-209334 10.1038/nrrheum.2017.188 10.3892/etm.2021.9999 10.1186/s13075-015-0640-3 10.1111/odi.12598 10.1038/s41586-020-2971-8 10.1038/s41584-020-00507-9 10.1186/ar2097 10.1002/art.41652 10.1002/art.41156 10.4049/jimmunol.166.4.2878 10.1136/ard.2006.062042 10.1038/s41467-020-18513-6 10.1002/art.39800 10.1016/0049-0172(73)90035-8 10.1136/annrheumdis-2012-202608 10.1136/annrheumdis-2013-204858 10.3899/jrheum.140182 10.1007/s11926-013-0316-4 10.1111/j.1468-3083.2011.04138.x 10.1093/rheumatology/keg384 10.1002/art.34536 10.1111/j.1756-185X.2012.01736.x 10.1111/j.1365-2133.2008.09023.x 10.3899/jrheum.130163 10.1093/rheumatology/30.4.245 10.1016/S0140-6736(15)00347-5 10.3899/jrheum.090412 10.1007/s002560050500 10.1136/ard.57.3.135 10.1136/annrheumdis-2016-209853 10.3899/jrheum.110845 10.1002/art.23104 10.1136/annrheumdis-2011-201081 10.1093/rheumatology/33.9.834 10.1093/rheumatology/38.4.332 10.3899/jrheum.091059 10.1136/ard.2003.018184 10.3899/jrheum.171406 10.1111/bjd.12190 10.1136/annrheumdis-2012-201706 10.1111/jdv.14971 10.1002/art.39494 10.3899/jrheum.160904 10.1002/acr.24242 10.1002/acr.20577 10.1016/j.semarthrit.2007.03.004 10.1016/j.semarthrit.2013.08.006 10.1136/ard.2008.094946 10.1016/j.rdc.2015.07.010 10.1038/nrrheum.2012.56 10.1093/rheumatology/kes001 10.1002/art.40851 10.1002/art.1780391210 10.1002/art.20253 10.1007/s40265-014-0191-y 10.1002/art.20967 10.1111/jcpt.12045 10.1016/S0140-6736(13)60594-2 10.1136/annrheumdis-2013-204655 10.1002/art.40728 10.1136/annrheumdis-2015-209068 10.1136/annrheumdis-2020-218808 10.1136/annrheumdis-2019-215386 10.1016/S0140-6736(20)30564-X 10.1056/NEJMoa1315231 10.1136/annrheumdis-2019-216835 10.1016/S0140-6736(19)33161-7 10.1016/S0140-6736(17)31474-5 10.1016/S0140-6736(20)30265-8 10.1016/S0140-6736(20)30263-4 10.1002/art.41553 10.1002/art.40759 10.1136/annrheumdis-2020-219014 10.1136/annrheumdis-2016-210724 10.1136/annrheumdis-2013-205056 10.3899/jrheum.151376 10.1136/annrheumdis-2015-207963 10.1056/NEJMoa1615975 10.1056/NEJMoa1615977 10.1136/annrheumdis-2019-216761 10.1136/annrheumdis-2020-218870 10.1016/S0140-6736(18)32483-8 10.1056/NEJMoa1806382 10.1002/art.40726 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T 10.1093/rheumatology/kev009 10.1136/annrheumdis-2014-205207 10.3899/jrheum.161459 10.1016/j.semarthrit.2020.10.010 10.1136/annrheumdis-2016-210242 10.1097/00005650-199206000-00002 10.1016/0168-8510(91)90141-J 10.1136/ard.2003.006296 10.3899/jrheum.181077 10.1186/s12955-020-01422-z 10.1007/s40744-020-00221-8 10.1136/annrheumdis-2018-215003 10.3899/jrheum.190083 10.1159/000499924 10.1016/j.semarthrit.2017.05.010 10.1093/rheumatology/keu264 10.1136/annrheumdis-2016-210579 10.1136/rmdopen-2020-001240 10.3899/jrheum.140259 10.1007/s00296-020-04678-2 10.1007/s10067-019-04734-8 10.1007/s12325-019-00901-0 10.1007/s00296-015-3377-z 10.4049/jimmunol.1700596 10.1186/s13075-019-2050-4 10.1186/s13075-019-1957-0 10.1093/rheumatology/kez457 10.1007/s11926-019-0876-z 10.1038/s41587-019-0392-8 10.1038/s41592-019-0392-0 10.1093/rheumatology/keaa880 10.1038/clpt.2011.321 10.1038/d41573-019-00072-1
Nature Reviews. Disease Primers; FitzGerald O, Ogdie A et. al.

Aug 14th, 2021 - Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying i...

see more →

Guidelines  1 results

Treatment of nail psoriasis: best practice recommendations from the Medical Board of th...
https://doi.org/10.1001/jamadermatol.2014.2983
JAMA Dermatology; Crowley JJ, Weinberg JM et. al.

Dec 5th, 2014 - Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide ...

see more →

Clinicaltrials.gov  1 results

Pulsed Dye Laser for the Psoriatic Nail
https://clinicaltrials.gov/ct2/show/NCT01303185

Dec 12th, 2014 - Psoriatic nails of patient's right hand were treated using PDL (595 nm) .The pulsed duration is 1.5ms, the beam diameter is 7mm, and the laser energy is 8.0 to 10.0 J/cm2. The treatment course of pulse dye laser is once monthly for 6 months. Psori...

see more →

News  26 results

We Have a Winner: Head-to-Head Study Compares Biologics for PsA
https://www.medpagetoday.com/rheumatology/arthritis/82499

Oct 1st, 2019 - Ixekizumab (Taltz) was superior to adalimumab (Humira) at 24 weeks in an open-label, ongoing, multicenter head-to-head trial evaluating both skin and joint symptoms in psoriatic arthritis (PsA), investigators reported. On the primary endpoint of t...

Comorbid skin conditions common in children with lichen nitidus
https://www.mdedge.com/familymedicine/article/195810/dermatology/comorbid-skin-conditions-common-children-lichen-nitidus?channel=39313
MDedge Pediatrics; Lucas Franki

Mar 6th, 2019 - Comorbid dermatologic conditions appear to be common in children with lichen nitidus, as is generalized disease, according to Selcen Kundak, MD, and Yasemin Çakır, MD, of Dr. Behcet Uz Children’s Research and Training Hospital in Izmir, Turkey.

Nail Psoriasis Tips
https://www.mdedge.com/dermatology/article/194086/hair-nails/nail-psoriasis-tips?channel=219
Jeffrey M. Weinberg, MD

Feb 7th, 2019 - What does your patient need to know at the first visit? Patient education is important initially. There are several causes for nail dystrophy.

A 4-year-old boy is brought to our pediatric dermatology clinic by his mother with the concern of difficult to treat toenail fungus.
https://www.mdedge.com/familymedicine/article/189739/dermatology/what-your-diagnosis-december-2018
MDedge Pediatrics; Catalina Matiz, MD

Nov 28th, 2018 - A KOH (potassium hydroxide) test done at the visit was negative as well as a fungal culture of each toenail. Dr.

IL inhibitor options move psoriasis treatment forward
https://www.mdedge.com/rheumatology/article/176354/psoriasis/il-inhibitor-options-move-psoriasis-treatment-forward
Heidi Splete

Oct 4th, 2018 - Psoriasis patients have many options, and more are on the way, according to J. Mark Jackson, MD, of the University of Louisville, Ky.

see more →